Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory trial of two nintedanib doses for generalized keloids
ChiCTR2400089943Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nintedanib in keloid (2 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Change in Vancouver Scar Scale score from baseline. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
keloid
Beyond the preview
Go deeper on ChiCTR2400089943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089943.